This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
by Zacks Equity Research
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
BIIBPositive Net Change BMYPositive Net Change ABBVPositive Net Change ALLOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
by Ekta Bagri
BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more room for growth, and any dip in share price can be used as a buying opportunity.
BMYPositive Net Change PFEPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
AZNPositive Net Change NVAXPositive Net Change PRTAPositive Net Change TBPHPositive Net Change AXSMPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
NVSPositive Net Change LLYPositive Net Change NKTRPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
NVSPositive Net Change BIIBPositive Net Change ALLOPositive Net Change IMVTPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
by Zacks Equity Research
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
SNYPositive Net Change BIIBPositive Net Change FOLDPositive Net Change DNLIPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy Quad/Graphics (QUAD) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
QUADNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.
GSKPositive Net Change GILDNegative Net Change EXELNegative Net Change FOLDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.
NVSPositive Net Change BIIBPositive Net Change CPRXPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
NVSPositive Net Change BIIBPositive Net Change PCRXNegative Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
NVSPositive Net Change BIIBPositive Net Change ACADPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
by Zacks Equity Research
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
NVSPositive Net Change NVOPositive Net Change LLYPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
by Zacks Equity Research
RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.
REGNPositive Net Change NVSPositive Net Change RAREPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?
by Zacks Equity Research
ADMA is having a stupendous run in 2024 so far on strong performance of Asceniv and high growth prospects.
GRFSNegative Net Change ADMAPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
by Zacks Equity Research
KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.
EXELNegative Net Change FOLDPositive Net Change AMRNPositive Net Change KRYSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
by Zacks Equity Research
EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.
NVSPositive Net Change VRTXPositive Net Change EDITPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Best Momentum Stocks to Buy for November 5th
by Zacks Equity Research
CORT, ZBRA and QUAD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 5, 2024.
QUADNegative Net Change CORTNegative Net Change ZBRANegative Net Change
biotechnology
3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday
by Nalak Das
We have narrowed our search to there large-cap stocks set to report results on Tuesday. These are: EXAS, DD and KGC.
DDNegative Net Change KGCPositive Net Change EXASPositive Net Change
basic-materials biotechnology gold
Gilead Science to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on GILD???s HIV franchise performance and oncology sales when the company reports third-quarter 2024 results.
GILDNegative Net Change SRPTPositive Net Change IONSPositive Net Change LEGNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
by Zacks Equity Research
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
NVSPositive Net Change BAYRYPositive Net Change ZTSPositive Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.
SNYPositive Net Change FOLDPositive Net Change AMRNPositive Net Change KYMRPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
NVSPositive Net Change BAYRYPositive Net Change MDGLNegative Net Change ALLOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
by Zacks Equity Research
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
by Zacks Equity Research
BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.
BMYPositive Net Change PFEPositive Net Change FOLDPositive Net Change AMRNPositive Net Change
biotechnology biotechs earnings pharmaceuticals